India’s Biotech Surge and its Scaling Challenges
Kartavya Desk Staff
Syllabus: Biotechnology
Source: TH
Context: India’s biotechnology sector has seen an exponential rise—from 500 startups in 2018 to over 10,000 in 2025—driven by policies like BioE3 and a target of a $300-billion bioeconomy by 2030.
About India’s Biotech Surge and its Scaling Challenges:
Growth in India’s Biotech Ecosystem:
• Exponential Startup Expansion: The number of biotech startups increased 20-fold (2018–2025), supported by 94 incubators across 25 States, reflecting India’s transition from generic manufacturing to deep-tech innovation.
• Affordable R&D Edge: India’s low-cost research ecosystem and young STEM talent pool enable competitive innovation.
• AI-Driven Research Integration: Biotech startups are integrating AI and data analytics for faster drug discovery and diagnostics.
• Global Vaccine Leadership: India supplies 60% of global immunisation doses (DPT, BCG, measles), underscoring its role as the “Pharmacy of the World.”
• Ambitious Bioeconomy Vision: The BioE3 Policy (2025) targets a $300-billion bioeconomy by 2030, positioning biotech as a national growth pillar alongside IT and energy.
Major Initiatives Taken:
• BIRAC (Biotechnology Industry Research Assistance Council): Provides seed funding, grants, and incubation support through programs like BIG and SBIRI, fostering over 6,000 startups.
• BioE3 Policy 2025: Integrates biomanufacturing, bio-agriculture, bioenergy, and biopharma into a unified framework aligned with SDG and Atmanirbhar Bharat goals.
• Production-Linked Incentive (PLI) for Biopharma: Encourages domestic production of critical raw materials and bulk drugs, reducing import dependency.
• FDI Liberalisation and Startup India: Allows 100% FDI in biotech, drawing global investors and partnerships.
Major Challenges:
• Funding Bottlenecks in Scale-up Phase: Early-stage funding is strong, but Series B/C rounds remain scarce, limiting transition from lab to market.
Eg: India attracted only $3 billion (2023–25)—far below China’s $12 billion for biotech scale-ups.
• Fragmented Infrastructure: 70+ incubators exist, but few offer end-to-end GMP or pilot-scale facilities, leading to duplication and delays.
Eg: Startups often travel between Hyderabad, Pune, and Bengaluru to complete one product cycle.
• Regulatory Outdatedness: Current clinical trial and patent regimes lag behind emerging technologies like CRISPR and AI-based therapeutics.
Eg: Delays in gene therapy approvals cost startups international collaborations and IP protection.
• Talent and Brain Drain: India loses over 40% of its biotech PhDs to overseas research hubs due to limited career pathways.
Eg: Countries like Singapore and South Korea offer better post-doc incentives and funding continuity.
• Limited Global Market Access: Indian firms face regulatory misalignment with the US FDA and EU EMA, restricting exports of high-value biologics.
Eg: Only 15% of Indian biosimilars meet EMA approval criteria due to data integrity gaps.
Strategic Priorities for Reform
Area | Proposed Action
Ecosystem Consolidation | Create biotech clusters (e.g., “GMP Commons” in Genome Valley, Mumbai–Pune corridor) pooling shared infrastructure.
Financing Mechanism | Establish dedicated biotech funds and blended-finance structures using venture debt and insurance capital.
Clinical Trial Hubs | Develop late-phase trial centres in AIIMS hospitals with integrated EHRs, centralised ethics committees, and labs.
Talent Reinforcement | Launch reverse brain drain schemes—tax incentives, relocation grants, micro-credential training (CRISPR, AI-biostatistics).
Regulatory Modernisation | Adopt risk-based, adaptive frameworks inspired by the EU AI Act and US FDA models for emerging biotech domains.
Way Ahead
• Create Biotech Clusters: Develop integrated “Bio Commons” hubs (Genome Valley, Mumbai–Pune corridor) for shared GMP and regulatory facilities.
Eg: Clustered models in Boston and Seoul cut scale-up costs by 25% and improved collaboration.
• Establish Dedicated Biotech Financing Fund: A National Bio-Venture Fund with blended financing can support companies post-proof-of-concept.
Eg: Matching equity + venture debt could unlock institutional capital from pension and insurance funds.
• Modernise Regulations: Introduce risk-based, adaptive frameworks aligned with EU AI Act and US FDA Predetermined Change Control Plans.
Eg: Faster approvals for low-risk biologics can cut market-entry delays by 6–12 months.
• Attract and Retain Talent: Launch reverse brain drain programmes with tax breaks, relocation incentives, and micro-credential courses in AI-biostatistics, CRISPR, GMP data integrity.
Eg: Israel’s “Return Home Program” boosted R&D capacity by 20%; a similar model can aid India.
• Public–Private Collaboration: Foster co-development partnerships between government labs, academia, and private firms.
Eg: The Serum Institute–Oxford collaboration during COVID-19 became a model for global biotech diplomacy.
Conclusion:
India’s biotech revolution stands at a crossroads — rich in ideas but constrained by structure. To translate its startup boom into global leadership, India must consolidate, capitalise, and collaborate. By aligning innovation with infrastructure and governance, India can truly evolve into the biotech capital of the Global South by 2030.